Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Gains from Investment Securities (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Gains from Investment Securities for 9 consecutive years, with $10000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Gains from Investment Securities changed N/A year-over-year to $10000.0, compared with a TTM value of $111000.0 through Sep 2025, down 20.14%, and an annual FY2023 reading of -$3000.0, down 101.12% over the prior year.
  • Gains from Investment Securities was $10000.0 for Q2 2025 at Lisata Therapeutics, down from $243000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $243000.0 in Q1 2025 and bottomed at -$142000.0 in Q4 2024.
  • Average Gains from Investment Securities over 3 years is $35714.3, with a median of $3000.0 recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 4833.33% in 2024, while the deepest fall reached 4633.33% in 2024.
  • Year by year, Gains from Investment Securities stood at -$3000.0 in 2023, then crashed by 4633.33% to -$142000.0 in 2024, then surged by 107.04% to $10000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for LSTA at $10000.0 in Q2 2025, $243000.0 in Q1 2025, and -$142000.0 in Q4 2024.